Clinical Application of Buzhong Yiqi Decoction Combined with Gemcitabine in Postoperative Non-Muscular Invasive Bladder Cancer
Objective To investigate the value of Buzhong Yiqi Decoction combined with gemcitabine in postoperative treatment of non-muscular invasive bladder cancer.Methods A total of 102 patients with non-muscular invasive bladder cancer who underwent surgical treatment from January 2022 to January 2024 at Shangluo Central Hospital were selected.They were randomly divided into a control group and an observation group,with 51 patients in each group.The control group received gemcitabine treatment after surgery,while the observation group received Buzhong Yiqi Decoction combined with gemcitabine.The clinical efficacy,TCM syndrome scores,immune function,and treatment safety were evaluated in both groups.Results The total effective rate of the observation group was higher than that of the control group ( P<0.05 ) .The TCM syndrome scores of the observation group were significantly lower than those of the control group ( P<0.05 ) .After treatment,the levels of CD4+,CD3+,and CD4+/CD8+in the observation group were higher than before treatment,and CD8+levels were lower than before treatment ( P<0.05 ) .There was no significant difference in the incidence of adverse reactions between the two groups ( P>0.05 ) .Conclusion Buzhong Yiqi Decoction combined with gemcitabine has a good effect in the postoperative application for non-muscular invasive bladder cancer,as it can alleviate the main TCM syndromes,improve immune function,and is safe for treatment.
Bladder cancerNon-muscular invasiveBuzhong Yiqi DecoctionGemcitabineImmune functionT lymphocyte subgroupsEfficacy comparison study
万方数据
维普
